Paid Clinical Trials in Galesburg, IL
As of September 2026, 75 paid clinical trials are recruiting in Galesburg, Illinois. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Galesburg offers studies at sites including Illinois CancerCare-Galesburg for conditions such as Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Acute Myeloid Leukemia. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Galesburg
Trials by drug in Galesburg
Filter results
75 clinical trials
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Family Communications After Genetic Testing
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Top Research Study Locations in Galesburg
Researchers run research studies in Galesburg, IL at 4 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Illinois CancerCare-Galesburg | Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | 71 |
| Western Illinois Cancer Treatment Center | Acral Lentiginous Melanoma, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma | 5 |
| Illinois CancerCare - Galesburg | Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) | 3 |
| Illinois CancerCare Galesburg | Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma, Non-small Cell Carcinoma | 1 |
Active & Upcoming Studies in Galesburg (2026)
Recruiting trials in Galesburg grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (65 active studies)
- Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) · Phase 2 · National Cancer Institute (NCI)
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial · Phase 3 · National Cancer Institute (NCI)
Mental health & behavior (2 active studies)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Common conditions studied in Galesburg
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Lung Non-Small Cell Carcinoma (5 active studies)
- Stage IV Lung Cancer AJCC v8 (5 active studies)
- Acute Myeloid Leukemia (4 active studies)
- Head and Neck Squamous Cell Carcinoma (4 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (4 active studies)
Leading research sponsors in Galesburg
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- National Cancer Institute (NCI)
- NRG Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Galesburg?
There are approximately 75 recruiting clinical trials in Galesburg, Illinois listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Galesburg pay participants?
Most recruiting trials in Galesburg compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Galesburg?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Galesburg?
The most common conditions under active study in Galesburg include Anatomic Stage II Breast Cancer AJCC v8 (5), Lung Non-Small Cell Carcinoma (5), Stage IV Lung Cancer AJCC v8 (5), Acute Myeloid Leukemia (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Galesburg?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Galesburg on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Galesburg?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Galesburg?
Recruiting research sites in Galesburg include Illinois CancerCare-Galesburg, Western Illinois Cancer Treatment Center, Illinois CancerCare - Galesburg, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Galesburg right now?
The largest active categories in Galesburg are Cancer & tumors (65), Mental health & behavior (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.